BKL is up more today and has been trending up over the last 3-4 weeks (despite all the China tax headwinds) because they report their quarterly financial results later this month (28 April). The smart money is positioning itself before they announce another great quarter given that it's the first quarter with their substantial vitamins price increase.
As BAL only report half yearly, there's no impetus to buy now as there's not likely to be any price sensitive announcements in the coming months and therefore plenty of time to buy seeing as it's likely to hover around the current price for a while. I think we'll see BAL start to report quarterly from next year. It will cost the company more to report quarterly, however, investors will be wanting more frequent reporting. How many companies in the ASX 200 report half yearly? That would be interesting to find out.
Also, a lot of people have been burnt buying BAL at higher prices and are staying clear now. It's currently trading at 5-month lows. The reputation of BAL stock has been dented, so will take a bit for sentiment to swing around.
- Forums
- ASX - By Stock
- BAL
- China's new 17% tax on imports
China's new 17% tax on imports, page-21
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online